| Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy (NCT00443690) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2007-08-01 |
| PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (NCT00354458) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2006-10-01 |
| PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (NCT00328692) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2006-08-01 |
| Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment (NCT00159614) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2005-09-01 |
| Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients (NCT00652782) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2004-12-01 |
| Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). (NCT00159627) | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2004-08-01 |